MaxCyte reported Q3 2024 revenue of $8.16 million, compared with a trailing four-quarter revenue base of roughly $45.6 million and a YoY revenue increase of 1.99%, but a QoQ decline of 21.72%. The quarter delivered a robust gross margin of 76.4% (gross profit of $6.24 million on $8.16 million revenue), yet the company remains firmly in a loss position with an operating loss of $14.05 million and a net loss of $11.56 million. EBITDA stood at $(12.99) million, producing an EBITDA margin of approximately (1.59%). These earnings reflect sustained high operating expenses, notably in SG&A and R&D, as MaxCyte continues to invest in product development and go-to-market capabilities for its ExPERT platform family and associated disposable processing assemblies. Despite the near-term profitability challenge, the balance sheet remains robust: cash and short-term investments total about $153.8 million, resulting in a net cash position of roughly $18.6 million (net debt of $(18.6) million). The company ended the period with a strong liquidity profile (current ratio ~9.81, quick ratio ~9.22) and substantial liquidity to weather near-term cash burn while pursuing longer-term top-line growth through cell therapy adoption and platform expansion.